Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)

Organon

Status and phase: Completed; Phase 3

Conditions: Asthma, Bronchial; Rhinitis, Allergic, Perennial

Treatments: Drug: Comparator: placebo; Drug: MK0476, montelukast sodium

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092105

0476-256

2004_024

Details and patient eligibility

About

The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.

Full description

The duration of treatment is 2 weeks.

Enrollment: 58 patients

Sex: All

Ages: 15 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Increased sensitivity to cat allergen proven by positive allergy testing, and by decreased lung function and increased symptoms of allergic rhinitis (runny nose) upon exposure to cats.

Exclusion criteria

• Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind